BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402

The first two patient cohorts included in total 200 individuals and the recruitment for the second cohort was concluded in August. The decision to start recruitment of the third patient cohort follows an unanimous recommendation from the external board monitoring the efficacy and safety of the study.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study will assess three different doses of TB-402 given as a single intravenous injection post knee replacement surgery and the trial will enrol 300 patients. The objective of the study is to assess the safety and efficacy of the three escalating doses of TB-402. All the patients in the study will be monitored for a period of three months after surgery. TB-402 is developed in collaboration with ThromboGenics NV.